术前与术后立体定向放疗的治疗实施、安全性与流程:一项随机临床试验的初步分析
这项单中心3期随机临床试验纳入103例接受计划性手术切除的脑转移患者,比较术前与术后立体定向放疗的流程与毒性。术前组45例(88%)完成放疗和手术,术后组38例(73%)完成;两组30天术后并发症无统计学显著差异;术前组手术至放疗中位时间6天,短于术后组22天(P < .001)。
要点
- 术前立体定向放疗与术后立体定向放疗的30天术后并发症无统计学显著差异。
- 术前组完成放疗和手术的比例为88%,术后组为73%。
- 术前组手术至放疗中位时间6天,术后组22天(P < .001)。
核心结论
- 在这项随机临床试验中,术前立体定向放疗的安全性可与术后立体定向放疗相比,并缩短了治疗完成时间,可能有助于加快诊疗流程。
研究设计与样本
- 单中心3期随机临床试验,纳入103例18岁及以上、计划接受手术切除的脑转移患者,按1:1随机分组。
- 术前组接受1至5次立体定向放疗后1个月内手术;术后组手术后1个月内接受术后立体定向放疗。
- 数据收集时间为2018年12月至2023年8月,数据分析时间为2023年9月至2024年12月。
主要发现
- 103例患者中56例(54.4%)为男性,中位年龄59岁(范围26-83岁)。
- 103例中83例(80.6%)在研究期间完成了脑转移的放疗和手术;其中70例(84%)入组时有1至4个脑转移灶,11例(13%)有5至10个病灶,2例(2%)有超过10个病灶。
- 术前立体定向放射外科/立体定向放疗组45例(88%)完成两种治疗,术后组38例(73%)完成。
- 两组30天术后并发症或术后事件无统计学显著差异。
- 术前组手术至放疗中位时间6天(范围0-24天),术后组22天(范围12-42天),P < .001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preoperative stereotactic radiation therapy (SRT) vs postoperative SRT logistics and toxic effects provides clinically significant data on management outcomes. OBJECTIVE: To determine preoperative SRT logistics and safety profile compared with postoperative in patients with brain metastases. DESIGN, SETTING, AND PARTICIPANTS: This single-institution phase 3 randomized clinical trial included patients 18 years and older and undergoing a planned surgical resection. Patients were required to have an Eastern Cooperative Oncology Group Performance Status score of 2 or greater and be candidates for SRT within 30 days of surgical resection. Patients with radiosensitive histologies (eg, small cell lung cancer and lymphoma), brain metastasis of unknown primary, and/or radiographic evidence of leptomeningeal disease were excluded. Data were collected from December 2018 to August 2023, and data were analyzed from September 2023 to December 2024. INTERVENTIONS: Patients were randomized 1:1. Patients randomized to the preoperative SRT cohort underwent SRT (in 1 to 5 fractions) followed by surgical resection within 1 month of radiation therapy. Patients randomized to the postoperative SRT cohort underwent resection followed by postoperative SRT within 1 month of surgery. MAIN OUTCOMES AND MEASURES: Outcomes reported focus on nonprimary end point analysis of the trial, including comparative toxic effect outcomes of preoperative vs postoperative SRT postprocedural events, feasibility of preoperative SRT, and radiation therapy management. RESULTS: Of 103 patients, 56 (54.4%) were male, and the median (range) age was 59 (26-83) years. Of 103 patients, 83 (80.6%) completed both radiation and surgery for brain metastases while in the study. Of these, 70 patients (84%) had 1 to 4 brain metastases at enrollment, 11 (13%) had 5 to 10 lesions, and 2 (2%) had more than 10 lesions. In the preoperative stereotactic radiosurgery (SRS)/SRT cohort, 45 (88%) completed both treatments compared with 38 (73%) in the postoperative SRS/SRT arm. There were no statistically significant differences between treatment groups in 30-day postoperative morbidity or postprocedural events. The median (range) time between surgery and SRT was significantly shorter in the preoperative arm (6 [0-24] days) compared with the postoperative arm (22 [12-42] days; P < .001). The median (range) time from randomization to receiving both brain-directed therapies was 10 (4-31) days in the preoperative arm compared with 32.5 (19-55) days for the postoperative arm (P < .001). CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, preoperative SRT had comparable safety to postoperative SRT and resulted in shorter time to treatment completion, potentially facilitating expedited care. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03741673.
引用
- Yeboa DN, Li J, Lin R, et al. Therapy, Safety, and Logistics of Preoperative vs Postoperative Stereotactic Radiation Therapy: A Preliminary Analysis of a Randomized Clinical Trial. JAMA Oncol. 2025. PMID: 40531511. doi:10.1001/jamaoncol.2025.1770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。